Brief: ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC
17/04/2024 14:20
April 17 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA EXECUTES A GLOBAL LICENSING DEFINITIVE
AGREEMENT
FOR THE TREATMENT OF NSCLC, EXPECTING AGGREGATE INCOME OF
$13.75M AND ROYALTIES OF UP TO $12.50M
* ABVC BIOPHARMA INC - TO RECEIVE $12.5M LICENSE FEE FROM
ONCOX
Source text for Eikon: ID:nGNX9FKNhR
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner